NTRK-TKI (** Vitrakvi (larotrectinib), Rozlytrek (entrectinib) **)

Other Medications

EU med_ema_approved ES med_spain_hospital_use med_crc_approved 1 Clinical Trials

Description

Larotrectinib and entrectinib are used in the treatment of solid tumors with NTRK gene fusions, including colorectal cancer (CRC) that harbors such alterations. These drugs have shown significant clinical activity in patients with advanced or metastatic CRC who have no satisfactory alternative treatments; however, their use is limited to a small subset of patients with specific genetic mutations.

Mechanism of Action

NTRK-TKIs, such as larotrectinib and entrectinib, inhibit the activity of tropomyosin receptor kinases (NTRK1/2/3) by binding to their ATP-binding sites, thereby blocking downstream signaling pathways that promote cell proliferation and survival.

Side Effects

Fatigue; nausea; constipation; dizziness; headache; muscle pain; joint pain; increased liver enzymes; QT interval prolongation

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04584008 Not Applicable
Active, not recruiting
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
China

Quick Info

Brand Name** Vitrakvi (larotrectinib), Rozlytrek (entrectinib) **
CategoryOther Medications
EU Estado EMAmed_ema_approved
ES Acceso Españamed_spain_hospital_use med_crc_approved
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.